The updated Medscheme specialised drug list for 2023 has been published

By HEOR Staff Writer

May 12, 2023

Reimbursement is still dependent on authorisation and benefit limits.

Some drugs included:
ANTIHEMORRHAGICS
Hemlibra

CARDIOVASCULAR SYSTEM
Volibris

DERMATOLOGICALS
Dupixent

ANTIVIRALS FOR SYSTEMIC USE
Epclusa

ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy

IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya

DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair

Reference url

Recent Posts

Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes

By HEOR Staff Writer

February 10, 2026

Unlocking Early-Stage Cancer Treatment Gains Early-stage cancer treatment offers significant clinical, humanistic, and economic advantages through timely detection and intervention, yet faces barriers like screening disparities, recurren...

European Pharma Competitiveness: A Cornerstone for EU Economic Resilience

By João L. Carapinha

February 9, 2026

European Pharma Competitiveness: Driving EU Economic Strength European pharma competitiveness is vital for the EU's trade surplus and future growth. How does the pharmaceutical sector boost EU competitiveness? It generate...

National HealthTech Access: Transforming NHS Adoption and Equity